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Neuroleptic malignant 
syndrome (NMS) is a rare 
disease occurring from an 
adverse reaction to anti-
psychotic use.  The diagnosis 
and predictability of the disease 
is extremely difficult as it mimics 
other syndromes (Margetić & 
Aukst-Margetić, 2010). The 
disease onset can occur when 
initiating medications, 
escalating doses, or adding an 
adjunctive anti-psychotic to the 
regimen.  Although causing the 
unpredictability, the disease can 
occur at any dose (Paul, 
Michael, John, & Lenox, 2012). 
Further increasing the difficulty 
of diagnostics, signs and 
symptoms are very wide spread. 
The Diagnostic and Statistical 
Manual of Mental Disorders 
created a tool to assist in the 
clinical setting; it, “requires the 
presence of 2 core features of 
severe muscle rigidity and 
elevated temperature after 
recent initiation or change in 
dosage of an antipsychotic, 
along with 2 or more of the 
following symptoms: 
diaphoresis, dysphagia, tremor, 
incontinence, changes in level of 
consciousness, mutism, 
tachycardia, elevated or labile 
blood pressure, leukocytosis, 
and elevated creatine kinase 
(CK) levels” (Paul, Michael, John, 
& Lenox, 2012). The basis of 
diagnostics have been primarily 
through simple exclusion of 
other syndromes and diseases.  
With this being said the biggest 
factor in decreasing the severity 
of NMS is disease timely 
diagnosis and treatment. 
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NMS has been a dilemma in the medical field. The pathophysiology has not been fully discovered. Diagnosis is rather 
difficult through mimicking of other syndromes and diseases. Types of treatments are controversial while standard medical 
practice has not been developed yet. The onset is unpredictable occurring at any dose. Standard practice for escalating 
doses of antipsychotic medication has only been made for a few such as quetiapine and clozapine (Langan, Martin, 
Shajahan, & Smith, 2012). After recovery re-challenging antipsychotic medication is still under debate. NMS is rare and 
typically self-limiting within 7-10 days if the antipsychotic medication is discontinued (Hashim, Zeb-un-Nisa, Alrukn, & Al 
Madani, 2014). Although there are those cases that are severe enough to cause respiratory and cardiovascular 
compromise. Nevertheless there is some information through evidence based practice that is certain.   Those with history 
of NMS are to be treated with single oral antiphyschotic medication with low doses and escalating as slow as possible 
(Ouyang & Chu, 2013). There is a much greater risk with using intravenous or intramuscular routes (Yanfen, Yahui, & Aiguo, 
2014).   Lastly and most important to note is that fast recognition and treatment have been proven to decrease the severity 
of symptoms.  
The pathophysiology of NMS is not completely 
understood, but there are theories and assumptions that 
have been found. The major dysfunction is thought to be 
due to sudden and profound decrease in dopamine D2 
receptor blockade (Paul, Michael, John, & Lenox, 2012). 
Signs and  
Symptoms 
Theory of pathophysiology 
Muscle rigidity Dopamine blockade in the 
nigrostriatal region 
Elevated or 
labile blood 
pressures 
Autonomic dysregulation of 
norepinephrine, serotonin, 
epinephrine; Dopamine is thought 
to play a role in interrupting the 
inhibitory pathways of the 
sympathetic nervous system 
(Margetić & Aukst-Margetić, 2010) 
Elevated CPK Muscle rigidity, rhabdomyolysis, 
agitation, physical muscle injury 
Elevated 
temperature 
Severe muscle rigidity, decreased 
dopamine in the hypothalamus 
(temperature control center of 
brain) 
Depiction of a case with NMS 
Retrieved from: http://epomedicine.com/wp-
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NMS although rare can be fatal. NMS has a spectrum of 
severity from minor to severe. It has been shown in 
evidence based practice that if NMS if diagnosed and 
treated early enough can drastically reduce the 
severity (McDermott, Noordsy, & Traum, 2013). It is 
important for clinicians and patients to watch for these 
signs and symptoms when escalating doses of 
antipsychotic medications or adding new or adjunctive 
antipsychotics. Those that live with the patients taking 
antipsychotics also need education to watch for these 
trigger signs.  
 
 
(Paul, Michael, John, & Lenox, 2012) 
NMS:  Devastating Effects 
Clinical Course Effects 
Altered level of 
consciousness 
Requirements of 
mechanical ventilation 
and use of restraints 
(Hashim, Zeb-un-Nisa, 
Alrukn, & Al Madani, 
2014) 
Elevated CPK Acute renal failure 
Dysphagia Risk for aspiration and 
long term NPO status 
leading to malnutrition 
Diaphoresis Skin breakdown 
Labile blood pressure Circulatory collapse and 
death 
Muscle rigidity and 
bradykinesia 
Risk for deep vein 
thrombosis, skin 
breakdown, 
rhabdomyolysis 
Elevated temperatures MRI imagine has shown 
damage to cerebellar and 
basal ganglia due to 
breakdown of membrane 
lipid, protein 
denaturation, and 
mitochondrial 
dysfunction (Lyons, & 
Cohen, 2013). 
The Dilemma In Conclusion 
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It is imperative for nursing to prevent secondary effects 
through appropriate positioning, hydration, frequent turning, 
close monitoring of vital signs and respiratory status, and 
daily skin assessments to name a few precautions.  
